| |
People To Watch
The Week Ahead: July 22 - 26, 2002
07.20.02, 12:00 PM ET
A look ahead to next week's doers and doings in business, entertainment and technology:
|
Background on Stewart | She was able to duck questions on the CBS Morning Show by focusing on her salad, but Martha Stewart will have nowhere to hide on Wednesday when her company, Martha Stewart Living Omnimedia
(nyse:
MSO -
news
-
people
), releases its second-quarter results. That's assuming the embattled goddess of good things chooses to participate in MSO's conference call. Analysts are looking for earnings per share of 15 cents, up from 11 cents in the year-ago quarter. |
|
|
|
| Richard Notebaert, the recently named CEO of Qwest Communications International
(nyse:
Q -
news
-
people
), could announce a deal as early as next week for his telephone directory business. Qwest says it has received "multiple bids" for the unit. Wall Street is hoping the sale will bring in as much as $10 billion; Notebaert needs to pay down the $26 billion in debt he inherited from his predecessor, Joseph Nacchio. |
Background on Notebaert |
|
|
|
| Tyco's
(nyse:
TYC -
news
-
people
) CEO resigned and was charged with tax fraud. Next the board kicked out the general counsel. And just after the quarter ended, the company spun out CIT for less than half its purchase price. Last time Tyco announced earnings, the company scrapped its previously announced breakup plan. Could Tyco have any more hairballs to cough up when lead director John Fort III leads its Tuesday morning earnings call? |
| Background on Fort |
|
|
|
Background on Gilmartin | Will Merck
(nyse:
MRK -
news
-
people
) Chief Executive Raymond Gilmartin buy another drugmaker? Gilmartin has steadfastly maintained that he would grow his company through research, but the merger of Pfizer
(nyse:
PFE -
news
-
people
) and Pharmacia
(nyse:
PHA -
news
-
people
) will make keeping up even more difficult. To make matters worse, Pfizer CEO Hank McKinnell threw down another gauntlet at the company's analyst meeting by saying that he wouldn't mind doing studies that compare Pfizer/Pharmacia's arthritis drug, Celebrex, head-to-head with Merck's Vioxx. |
|
|
|
| Will Dan Vasella ever do a deal? The Novartis
(nyse:
NVS -
news
-
people
) chief executive talks about having the urge to merge, but then says that potential partners are too pricey, or that other CEOs, like Roche's Franz Humer, aren't about to sell. But it's not up to Humer whether Roche, which is family-owned, will be for sale. And the new partnership between Pfizer and Pharmacia could lead Vasella to decide he needs to buy someone to keep up. |
Background on Vasella |
|
|
 |
 |
|
 |
|
 |
 |
|
 |
 |
|
|
Save $64
on your Forbes Subscription!
17 issues for only $19.99
Risk-Free Money-Back Guarantee
|
|
|
 |
 |
|
 |
 |
|
 |
|
 |
|
 |
|
|
Forbes.com offers you access to some of the world's best investment advisors and commentators. Combine our helpful analysis with our useful investing tools to make the most of your investments.
